Inhibitor Therapeutics, Inc.·4

Jun 1, 4:15 PM ET

Vasisht Niraj 4

4 · Inhibitor Therapeutics, Inc. · Filed Jun 1, 2026

Research Summary

AI-generated summary of this filing

Updated

Inhibitor Therapeutics (INTI) Director Vasisht Niraj Receives Award

What Happened Vasisht Niraj, a director of Inhibitor Therapeutics, received an award of 50,000 shares of restricted common stock on May 5, 2026. The shares were acquired at $0.00 (no cash paid) as compensation under the company’s 2025 Equity Incentive Plan. This is an award/grant transaction (not an open-market purchase or sale).

Key Details

  • Transaction date: 2026-05-05; acquisition type: Award/Grant (code A); price: $0.00 for 50,000 shares.
  • Shares owned after transaction: Not specified in the Form 4 filing.
  • Footnote: Represents restricted common stock issued pursuant to the Issuer's 2025 Equity Incentive Plan.
  • Filing date: 2026-06-01 — the Form 4 was filed approximately 27 days after the transaction (appears late; transactionTimeliness = 'L').

Context Restricted stock awards are typically compensation subject to vesting and other conditions, so they do not necessarily indicate immediate sellable ownership or a direct market sentiment. Awards to directors are common as part of compensation programs and are different from open-market purchases, which some investors view as a stronger bullish signal.

Insider Transaction Report

Form 4
Period: 2026-05-05
Transactions
  • Award

    Common Stock

    [F1]
    2026-05-05+50,000200,000 total
Footnotes (1)
  • [F1]Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.
Signature
/s/ Niraj Vasisht|2026-06-01

Documents

1 file
  • 4
    ownership.xmlPrimary

    4